絞り込み

16525

広告

「"ann rheum dis"[Journal]」の検索結果

14532件中 41件~60件表示    検索結果をPubMedで見る PubMedで見る

Response to: 'Variation in antinuclear antibody detection by automated indirect immunofluorescence analysis' by van Hoovels .

Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.

Platelet activation, as measured by plasma soluble glycoprotein VI, is not associated with disease activity or ischaemic events in giant cell arteritis.

To DAPSA or not to DAPSA? That is not the question.

Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis.

Tofacitinib in steroid-dependent relapsing polychondritis.

Exposure to passive smoking and rheumatoid arthritis risk: results from the Swedish EIRA study.

Metabolic pathways and immunometabolism in rare kidney diseases.

Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.

Urinary epidermal growth factor predicts renal prognosis in antineutrophil cytoplasmic antibody-associated vasculitis.

Response to: 'Time to personalise the treatment of anti-MDA-5 associated lung disease' by Lake .

EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis.

Checkpoint inhibitor-associated immune arthritis.

Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier.

visualisation of different modes of action of biological DMARDs inhibiting osteoclastic bone resorption.

Imputation-based analysis of alleles in the susceptibility to ankylosing spondylitis.

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります